A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Umeclidinium/vilanterol (Primary) ; Salmeterol; Umeclidinium
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 27 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jul 2017 Planned End Date changed from 27 Jun 2018 to 11 Jul 2018.
- 06 Jul 2017 Planned primary completion date changed from 27 Jun 2018 to 11 Jul 2018.